



# Investigating Long-Term Effects of Myocarditis

How CDC Is Investigating Myocarditis Health Effects after COVID-19 Vaccination

Updated July 20, 2022

#### What You Need to Know

- CDC is conducting surveys of patients (or their parents or guardians) and healthcare providers to gather information about myocarditis after COVID-19 vaccination.
- CDC is contacting people who meet the case definition for myocarditis following COVID-19 vaccination.

### Participating in the Survey

CDC is contacting people who meet the case definition for myocarditis following COVID-19 vaccination and have been reported to the Vaccine Adverse Event Reporting System (VAERS). To meet the case definition, people must have had:

- Symptoms such as chest pain, shortness of breath, and feelings of having a fast-beating, fluttering, or pounding heart and
- Medical tests to support the diagnosis of myocarditis and rule out other causes.
- CDC will contact people with myocarditis reported to VAERS after at least 90 days have passed since myocarditis symptoms began and will publish data as it becomes available.
- People may get a letter in the mail or receive a phone call from CDC asking questions about their myocarditis and medical history.
- Personal information and responses will be kept private to the extent allowable under the law. When the patient is a minor, a parent or legal guardian will be invited to participate on their behalf.

#### How did CDC get my contact information?

CDC got your contact information from the Vaccine Adverse Event Reporting System (VAERS \(\tilde{L}\)), a secure system that contains information needed to check in with patients to see how they are recovering after they experience a serious event following vaccination.

The U.S. Food and Drug Administration (FDA) **requires** healthcare professionals to report to VAERS certain serious adverse events and hospitalizations that occur after COVID-19 vaccination.

### How is CDC using my information?

The information you provide will contribute to what we know about the safety of COVID-19 vaccines, which helps us get a more complete picture of the risks and benefits of COVID-19 vaccination.

Personal details that could identify you will be kept private and information about your case will be combined with information from other participants. This means **your name and any identifying information will not be included in any reports.** CDC and FDA will use this information to guide recommendations on the safe use of COVID-19 vaccines.

For you and others who experienced myocarditis after receiving an mRNA vaccine, scientists will be looking at health effects such as:

- Changes in your health, physical ability, or quality of life
- How your heart recovers from myocarditis

### Why is CDC contacting my healthcare provider?

Having information on medications you take and your test results can provide a more complete picture of your health following myocarditis. Your healthcare provider can provide this information, which is important as we try to understand more about myocarditis after COVID-19 vaccination.

## How to Report Health Problems after Vaccination

You or your healthcare professional **can** report any adverse events or health problems after COVID-19 vaccination to VAERS by filling out an online form  $\square$  or a PDF form  $\square$ .

FDA **requires** healthcare professionals to report certain adverse events distribution that occur after administering COVID-19 vaccine, but **anyone can submit a report to VAERS**, **including you**.

Reports to VAERS are important to understanding the safety of COVID-19 vaccines as more people receive them over time. If you need further assistance with reporting to VAERS, please email info@VAERS.org or call 1-800-822-7967.

#### **Related Pages**

- > Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination
- > COVID-19 Vaccine Safety and Monitoring
- > Benefits of Getting a COVID-19 Vaccine
- Myths and Facts about COVID-19 Vaccines

#### More Information

Case Definition for Myocarditis following mRNA COVID-19 Vaccination

COVID-19 Vaccine Safety Publications